Image Source: Pixabay

TM Editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Sweden-based Elekta (EKTAF) develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy.

The company's installed base of more than 5,000 linear accelerators, GammaKnife, and Unity platforms, and software is used in more than 6,000 hospitals globally.

The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and Asia-Pacific contributing the remainder.

The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Three key data points gauge Elekta AB or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether any company has made, is making, and will make money.

EKTAF Price

Over the past year, Elekta's share price fell about 9.4% from $8.34 to $7.56 as of Monday’s market close.

If Elekta shares trade in the range of $6.50 to $10.00 this next year, its recent $7.56 share price might rise to $9.10 by next year. Of course, Elekta’s price could drop about the same $1.54 estimated amount or more.

My annual upside estimate of $1.54 however, is just $0.03 above Elekta’s average annual price gain over the past twenty months.

EKTAF Dividend

Elekta AB  has paid variable annual dividends since September 2014, converting to semi-annual mode as of April 2021. Elekta’s most recent SA dividend of 0.12 was declared on 7/13/23 for shareholders of record 2/26/24 and the payout was made on 3/1/24.

A forward-looking $0.23 annual dividend yields 3.04% at Monday’s $7.56 share price.

EKTAF Returns

To put it all together, add Elekta AB's estimated annual dividend of $0.23. to the estimated price upside of $1.54 to find a $1.77 estimated gross gain for the coming year.

At Monday’s $7.56 share price, a little under $1000 would buy 132 shares.

A $10 broker fee (if charged), paid half at purchase and half at sale, would cost us about $0.0.75 per share.

Subtracting that likely $0.075 brokerage cost from the $1.77 gross gain reveals a net gain of $1.695 X132 shares = $223.74 for a 22% estimated net gain on the year.

You might choose to pounce on Elekta AB. It is a 52-year-old dividend-paying Stockholm, Sweden-based neurosurgery equipment and supplies firm.  Furthermore, its estimated $30.40 annual dividend income from $1k invested is just over 4 times greater than Elekta’s recent $7.56 share price.

The exact track of Elekta AB’s upcoming future price and dividend will entirely be determined by market action.

Remember the true value of any stock is best realized through personal ownership of shares.

More By This Author:

Current Analysis: CompuGroup Medical (CMPVF)
Current Analysis: Xerox Holdings Corporation
Current Analysis: United Microelectronics